Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up (CRAD001AILO2)
Phase IV: Effect of Everolimus and CNI Minimalization on Renal Function.
The different mechanisms of action of Everolimus and cyclosporine suppress immune function in synergistic manner. Thus it is postulated that the use of Everolimus in combination with cyclosporine permits a significant cyclosporine dose reduction without loss of immunosuppressive activity in the clinical setting.
The aim of the present study is to evaluate the evolution of renal function after initiation of Everolimus and minimalisation of CNI dose.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Everolimus is a new proliferation signal inhibitor with immunosuppressive and antiproliferative activity.
The mechanism of action of Everolimus is distinct from that of calcineurin inhibitors.
Cardiac allograft vasculopathy is the major cause of late death in cardiac transplant patients.
The different mechanisms of action of Everolimus and cyclosporine suppress immune function in synergistic manner. Thus it is postulated that the use of Everolimus in combination with cyclosporine permits a significant cyclosporine dose reduction without loss of immunosuppressive activity in the clinical setting.
The aim of the present study is to evaluate the evolution of renal function after initiation of Everolimus and minimalisation of CNI dose.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Petah Tikva, Israel, 49100
- Cardiology Department, Rabin Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 year
- Signed informed consent
- 6 months to 15 year after heart transplantation
- Stable heart allograft function without rejection for at least 12 months
- Same immunusuppressive drugs for at least 3 months
- CNI based immunusuppression, with Cyclosporin levels C0 100-200 ng/ml FK levels of 5-10 ng/ml for preserved CNI levels.
- Poor renal function: creatinine > 1.5 mg%.
Exclusion Criteria:
- Suspected non-compliance
- Intolerance to Everolimus
- Life expectancy < 1year
- Proteinuria > 1.5 g/24u/1.73m2
- Previous sirolimus treatment
- Patients who received any other investigational drug
- Patients with platelet count <50,000/mm³ before baseline.
- Presence of severe hypercholesterolemia (≥350 mg/dL; ≥9 mmol/L) or hypertriglyceridemia (≥750 mg/dL; ≥8.5 mmol/L)
- Patients with an absolute neutrophil count of ≤ 1,500/mm3 or white blood cell count of ≤ 4000/mm³ at baseline
- Patients with a known hypersensitivity to similar drugs and to the components of the formulations
- Patients being treated with terfenadine, astemizole, or cisapride.
- Patients who are treated with drugs strong inducers or inhibitors of cytochrome P450 3A4.
- Patients with any past (within the past 5 years) or present malignancy (other than excised basal cell carcinoma)
- Patients with clinically significant systemic infection.
- Existence of any surgical or medical condition, which in the opinion of the investigator, might significantly alter the absorption, distribution, metabolism and excretion of study medication, and/or the presence of severe diarrhea or active peptic ulcer.
- Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Everolimus, Immunosupression
everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
|
reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evolution of renal function after initiation of Everolimus and minimalisation of CNI dose.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The occurrence of major adverse cardiovascular events
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tuvia Ben Gal, MD, Rabin Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 004765
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.